The St. Jude “bioactive” compound library used in this study consisted of 4364 unique compounds (a total of 8904 compounds including replicates) acquired from commercial sources (Microsource, Prestwick, and Sigma-Aldrich) and external academic collaborators or synthesized in-house by our chemistry group. It includes FDA-approved drugs or clinical candidates (913), nuclear hormone receptor ligands (108), the GSK published kinase toolset (358), kinase inhibitors (1,642), nuclear hormone receptor–based pharmacophore library (744), artemisinin-like compounds (535), certain rare chemical scaffolds (1665), and some other chemicals with reported biological activities (2939). The purity of purchased and in-house prepared chemicals was >85% and >90%, respectively. All chemicals were solubilized in DMSO at a stock concentration of 10 mM.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。